Afshar, M, Moallem S A, Mohammadpour A H, Shiravi A, Jalalian S M,Golalipour J. 2010. Teratogenic effects of carbamazepine on embryonic eye development in pregnant mice. Cutan Ocul Toxicol, 29: 10-15.
Ahmadi-Ashtiani, H, Allameh A, Rastegar H, Soleimani M,Barkhordari E. 2012. Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mesenchymal stem cells: comparison with glutathione modifiers. J Nat Med, 66: 85-94.
Ahmadi-ashtiani, H, Rezazadeh S, Safipourian K, Afraz K, Khaki A,Rastegar H. 2010. Study the Effects of Oral Administration of Silymarin in Preventing Consequences of Ethanol on Liver during Pregnancy. J Med Plants, 9: 143-150.
Badawy, G, El-Sayyad H L,Al-Shahar E E. 2011. Maternal and neonatal toxicities induced by three antirheumatic drugs in albino rats. J Am Sci, 7: 783-793.
Burdan, F, Dudka J, Szumilo J, Korobowicz A,Klepacz L. 2003. Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod Toxicol, 17: 413-419.
Burdan, F, Pliszczynska-Steuden M, Rozylo-Kalinowska I, Chalas A, Rozylo T K, Staroslawska E, Klepacz R,Szumilo J. 2011. Developmental outcome after exposure to cyclooxygenase inhibitors during pregnancy and lactation. Reprod Toxicol, 32: 407-417.
Burdan, F, Szumilo J,Klepacz R. 2009. Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol, 28: 239-244.
Campos, R, Garrido A, Guerra R,Valenzuela A. 1989. Silibinin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 55: 417-419.
Chan, L Y, Chiu P Y, Siu S S,Lau T K. 2001. A study of diclofenac-induced teratogenicity during organogenesis using a whole rat embryo culture model. Hum Reprod, 16: 2390-2393.
Etemad, L, Jafarian A H,Moallem S A. . Pathogenesis of Pregabalin-Induced Limb Defects in Mouse Embryos. J Pharm Pharm Sci, 18: 882 - 889.
Fraschini, F, Demartini G,Esposti D. . Pharmacology of Silymarin. Clin Drug Investig, 22: 51-65.
Fukushima, R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka R I, Kaneto M, Nakamura K,Kato I. . Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol, 24: 310-316.
Giannola, C, Buogo F, Forestiere G, Scaffidi L, Ferrigno V,Scaffidi A. 1985. A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency. Clin Ter, 114: 129-135.
Gilroy, D W, Tomlinson A, Greenslade K, Seed M P,Willoughby D A. 1998. The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Inflammation, 22: 509-519.
Karimi, G, Vahabzadeh M, Lari P, Rashedinia M,Moshiri M. 2011. Silymarin, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci, 14: 308-317.
Kasim, M J, Zheen A A, Intesar T N,Saad Abdul R H. 2009. Dose-dependent anti-inflammatory effect of silymarin in experimental animal model of chronic inflammation. Iraqi J Pharm Sci, 3: 242-247.
Kaur, A K, Wahi A K, Brijesh K, Bhandari A,Prasad N. 2011. Milk thistle (Silybum marianum): A review. IJPRD 3: 1-10.
Kimmel, C A,Trammell C. 1981. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol, 56: 271-273.
Mahabady, M K,Varzi H N. 2011. Prophylactic Effects of Silymarin and Vitamin E on Cyclophosphamide-Induced Skeletal Malformations in Rat Embryos. World Appl Sci J, 12: 636-641.
Malekinejad, H, Taheri-Broujerdi M, Moradi M,Tabatabaie S H. 2011. Silymarin potentiates the antinociceptive effect of morphine in mice. Phytother Res, 25: 250-255.
Mallikarjuna, G, Dhanalakshmi S, Singh R P, Agarwal C,Agarwal R. 2004. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res, 64: 6349-6356.
Metcalfe, A D, Hunter H R, Bloor D J, Lieberman B A, Picton H M, Leese H J, Kimber S J,Brison D R. 2004. Expression of 11 members of the BCL-2 family of apoptosis regulatory molecules during human preimplantation embryo development and fragmentation. Mol Reprod Dev, 68: 35-50.
Muriel, P, Garciapina T, Perez-Alvarez V,Mourelle M. 1992. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12: 439-442.
Nwadinigwe, C U,Anyaehie U E. 2007. Effects of cyclooxygenase inhibitors on bone and cartilage metabolism. Niger J Med, 16: 290-294.
Polyak, S J, Ferenci P,Pawlotsky J M. 2013. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology, 57: 1262-1271.
Pradhan, S C,Girish C. 2006. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res, 124: 491-504.
Sharma, m, Anwer T, Pillai K K, Haque S H, A K Najmi A K,Sultana Y. 2008. Silymarin, a flavonoid antioxidant, protects streptozotocin-induced lipid peroxidation and β-Cell damage in rat pancreas. Orient Pharm Exp Med, 8: 146-153.
Sorní, C, Sánchez R, Pellicer P,Andrés J P. 2005. Leflunomide: assessing teratogenic risk during the first trimester of pregnancy. Farm Hospital, 29: 265-268.
Torchinsky, A, Fein A,Toder V. 2005. Teratogen-Induced Apoptotic Cell Death: Does the Apoptotic Machinery Act As a Protector of Embryos Exposed to Teratogens? Birth Defects Res C, 75: 353-361.
Urban, M. 2000. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs. Orthopedics, 23: S761-764.
Woo, S M, Min K J, Kim S, Park J W, Kim D E, Chun K S, Kim Y H, Lee T J, Kim S H, Choi Y H, Chang J S,Kwon T K. 2014. Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation. Chem Biol Interact, 25: 36-43.